Pulsar-18 T3

Vascular Intervention // Peripheral
Self-Expanding Stent System/0.018”/OTW
 
Pulsar®-18 T3
 
 


 
 
 
 
 
 
 
 

 
 
 
 
 
 

 

Pulsar-18 T3


Indicated for use in patients with atherosclerotic disease of the superficial femoral, proximal popliteal and infrapopliteal arteries and for the treatment of insufficient results after Percutaneous Transluminal Angioplasty (PTA), e.g. residual stenosis and dissection.*

Technical Data

Stent
Catheter type OTW
Recommended guide wire 0.018”
Stent material Nitinol
Strut thickness 140 μm
Strut width 85 μm
Stent coating proBIO® (Amorphous Silicon Carbide)
Stent Markers 6 gold markers each end
Sizes ø 4.0 - 7.0 mm: L:20 - 200 mm
Shaft 4F, hydrophobic coating, tri-axial
Usable length 90 cm and 135 cm

Ordering Information

Stent ø (mm) Catheter length 90 cm (Stent length mm)
  20** 30 40 60 80 100 120 150 170 200
4.0 (4F) 430437 430438 430439 430440 430441 430442 430443 430444 430445 430446
5.0 (4F) 430447 430448 430449 430450 430451 430452 430453 430454 430455 430456
6.0 (4F) 430457 430458 430459 430460 430461 430462 430463 430464 430465 430466
7.0 (4F) 430467 430468 430469 430470 430471 430472 430473 430474 430475 430476
Stent ø (mm) Catheter length 135 cm (Stent length mm)
  20** 30 40 60 80 100 120 150 170 200
4.0 (4F) 430477 430478 430479 430480 430481 430482 430483 430484 430485 430486
5.0 (4F) 430487 430488 430489 430490 430491 430492 430493 430494 430495 430496
6.0 (4F) 430497 430498 430499 430500 430501 430502 430503 430504 430505 430506
7.0 (4F) 430507 430508 430509 430510 430511 430512 430513 430514 430515 430516
                    **8 weeks pre-order only

Contact

contact
Country/Region

1 BIOTRONIK data on file. 6.0 mm diameters;

2 BIOTRONIK data on file. 6.0 mm diameters. Supera stent not possible to test due to its design and applied test method;

3 Zhao HQ Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc. Interv. Radiol. 2009; 32(4); 720-6;

4 Koskinas C. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. JACC 2012 10;59(15):1337-49;

5 Koppara T. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv. 2015 8(6):e002427;

6 Funovics M. Correlation between chronic outward force (COF) and neointimal hyperplasia in self-expanding nitinol stents in swine in clinically relevant oversizing ranges. Presented at: LINC, Jan 26, 2017; Leipzig, Germany;

7 Bosiers M et al. 4-French – compatible endovascular material is safe & effective in the treatment of femoropopliteal occlusive
disease: Results of the 4EVER Trial. ENDOVASC THER 2013; 20: 746-756;

8 BIOTRONIK data on file;

9 Lichtenberg M. Superficial Femoral Artery TASC D registry: 12-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013 ; 54(4):433-9;

10 Lichtenberg et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions - the BIOFLEX PEACE All-Comers Registry.Vasa (2019), 1-9. doi_10.10240301-1526a000785;

11 Supera IFU, EL2100430 (2016-03-23);

12 Bosiers M. 4EVER 24 month results: long-term results of 4F Pulsar stent in femoropopliteal lesions. Presented at: CIRSE 2013; Barcelona, Spain;

13 Bunte M et al. in STROLL Catheterization and Cardiovascular Interventions 2018; 92:106-114;

14 Laird J et al. RESILIENT SFA nitinol stenting. JET 2012;19:1-9;

15 Dake M et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Am Heart Assoc 133.15 (2016): 1472-1483. doi: 10.1161/CIRCULATIONAHA.115.016900;

16 Rocha-Singh et al. DURABILITY II Three-Year Follow-up. Catheterization and Cardiovascular Interventions 2015; 86:164-170.

Leading competitors have been selected based on the PV Stent Revenue Market Shares EU, 2017 and PV Revenue Market Shares APAC 2015; (Source: Millennium Research Group Inc.). Latest SFA self expanding stents for each manufacturer; Zilver and Zilver Flex are trademarks or registered trademarks of Cook Medical Technologies or its affiliates. Innova is a trademark or registered trademark of Boston Scientific or its affiliates. Everflex and Entrust are trademarks or registered trademarks of Medtronic or its affiliates. Lifestent is a trademark or registered trademark of C. R. Bard or its affiliates. Supera is a trademark or registered trademark of the Abbott Group of Companies. S.M.A.R.T. Control is a trademark or registered trademark of Cardinal Health or its affiliates.

*Indication as per IFU.

Pulsar and proBIO are trademarks or registered trademarks of the BIOTRONIK Group of Companies.